Omeros Corporation (OMER)

Currency in USD
3.780
-0.080(-2.07%)
Closed·
After Hours
3.800+0.020(+0.53%)
·
OMER Scorecard
Full Analysis
Operates with a significant debt burden
OMER is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.6953.909
52 wk Range
2.95013.600
Key Statistics
Prev. Close
3.86
Open
3.86
Day's Range
3.695-3.909
52 wk Range
2.95-13.6
Volume
498.91K
Average Volume (3m)
1.29M
1-Year Change
-8.92%
Book Value / Share
-3.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OMER Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.500
Upside
+495.24%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Omeros Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Omeros Corporation Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation Earnings Call Summary for Q1/2025

  • Q1 2025 net loss of $33.5M ($0.58/share), meeting analyst expectations; stock rose 5.82% in aftermarket trading
  • Total debt reduced by $10M; cash and investments at $52.5M as of March 31, 2025
  • Narsoplimab BLA resubmission to FDA progressing; company preparing for potential commercial launch
  • OMIDRIA royalties contributed $6.7M in Q1; focus on top 40 transplant centers for narsoplimab launch
  • Seeking additional capital through partnerships; CEO confident in narsoplimab as first approved TATMA treatment
Last Updated: 15/05/2025, 22:18
Read Full Transcript

Compare OMER to Peers and Sector

Metrics to compare
OMER
Peers
Sector
Relationship
P/E Ratio
−1.5x−0.1x−0.5x
PEG Ratio
0.040.050.00
Price/Book
−1.2x2.5x2.6x
Price / LTM Sales
-1.4x3.3x
Upside (Analyst Target)
-130.8%43.5%
Fair Value Upside
Unlock33.9%6.9%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 22.500
(+495.24% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.58 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

OMER Income Statement

People Also Watch

17.96
SRPT
+10.46%
5.48
REPL
-0.36%
3.52
ALT
-2.22%
70.02
ABVX
+1.35%
1.280
SQNS
+1.59%

FAQ

What Stock Exchange Does Omeros Trade On?

Omeros is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Omeros?

The stock symbol for Omeros is "OMER."

What Is the Omeros Market Cap?

As of today, Omeros market cap is 256.09M.

What Is Omeros's Earnings Per Share (TTM)?

The Omeros EPS (TTM) is -3.04.

When Is the Next Omeros Earnings Date?

Omeros will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is OMER a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Omeros Stock Split?

Omeros has split 0 times.

How Many Employees Does Omeros Have?

Omeros has 202 employees.

What is the current trading status of Omeros (OMER)?

As of 08 Aug 2025, Omeros (OMER) is trading at a price of 3.78, with a previous close of 3.86. The stock has fluctuated within a day range of 3.70 to 3.91, while its 52-week range spans from 2.95 to 13.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.